Clinical Trials
477 trialsA Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
REVALLO
University Hospital, Bordeaux
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
IDARA
University Hospital, Caen
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Connect® MM- The Multiple Myeloma Disease Registry
Celgene
CPIT001
Hackensack Meridian Health
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Novartis
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
iinnovate-3
Teva Branded Pharmaceutical Products R&D, Inc.
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
RE-NEZ-SENS
University Hospital, Montpellier
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Novartis
CARTIFAN-1
Nanjing Legend Biotech Co.
TOMMY
Institut Cancerologie de l'Ouest
DC15-MM-01
Cartesian Therapeutics
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
M.D. Anderson Cancer Center
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Incyte Corporation
LIMBER
Incyte Corporation
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
University of Pennsylvania
AMBROBiMM
Assistance Publique - Hôpitaux de Paris
KarMMa-7
Celgene
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Mayo Clinic
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
University of Texas Southwestern Medical Center
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Shanghai Changzheng Hospital
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Amgen
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
CART-38 in Adult AML and MM Patients
University of Pennsylvania
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen